Home regimen
 

Keywords :   


Tag: regimen

Medication Regimen Review Software targets LTC industry.

2014-03-21 13:30:56| Industrial Newsroom - All News for Today

Designed for consultant pharmacists in Long Term Care industry, RxPertise™ Consulting Software v8.9 helps manage utilization, outcomes, and reporting requirements for residents. Standard Edition, intended for smaller LTC pharmacies and practice groups, provides flexible data management tools with importing and data merging functions. For large, multi-site operations, Enterprise Edition provides server-based MRR solution populated with pharmacy's own proprietary data sets. This story is related to the following:Medical & Health Care Software |

Tags: software review industry targets

 

Mercks Investigational Hepatitis C Treatment Regimen MK-5172/MK-8742 Shows Robust Anti-HCV Activity in HIV/HCV Co-Infected Patients with HCV Genotype 1 Infection

2014-03-05 22:15:00| Merck.com - Research & Development News

Dateline City: BOSTON BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor. Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639orIan McConnell, 908-423-3046orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: shows activity treatment patients

 
 

New 96-Week ACTG Study Results Presented at CROI 2014; First Large Study Comparing ISENTRESS (raltegravir) Regimen to Two Protease Inhibitor Regimens in Previously Untreated Adults with HIV-1

2014-03-05 18:15:00| Merck.com - Product News

Dateline City: BOSTON BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today that in a new 96-week, open-label AIDS Clinical Trials Group (ACTG) study designed to compare three different NNRTI-sparing HIV regimens in treatment-nave patients one containing Mercks twice-daily ISENTRESS (raltegravir) and two containing different once-daily ritonavir-boosted protease inhibitors, atazanavir and darunavir -- all three regimens achieved high and equivalent levels of efficacy, as measured by time to virologic failure (V Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639orSarra Herzog, 201-669-6570orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with results large study

 

Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma

2013-12-18 13:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the companys investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKlines orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: advanced cell combination evaluate

 

U.S. FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen...

2013-12-14 19:29:39| Biotech - Topix.net

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera for use in certain virologically-suppressed and St. John's wort.

Tags: single tablet fda approves

 

Sites : [1] [2] [3] [4] next »